Ganaxolone
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Ganaxolone |
| DrugBank ID | DB05087 |
| Brand Names (EU) | Ztalmy |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 94.85% |
Approved Indication (EMA)
Ztalmy is indicated for the adjunctive treatment of epileptic seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients 2 to 17 years of age. Ztalmy may be continued in patients 18 years of age and older.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | alcohol withdrawal delirium | 94.85% | DL |
| 2 | hallucinogen abuse | 93.07% | DL |
| 3 | barbiturate abuse | 93.07% | DL |
| 4 | antidepressant type abuse | 93.07% | DL |
| 5 | phencyclidine abuse | 82.76% | DL |
| 6 | alcohol withdrawal | 81.80% | DL |
| 7 | autism spectrum disorder | 79.30% | DL |
| 8 | gaze palsy, familial horizontal, with progressive scoliosis | 77.04% | DL |
| 9 | asperger syndrome, susceptibility to | 76.13% | DL |
| 10 | autism susceptibility 1 | 75.45% | DL |
| 11 | drug dependence | 74.69% | DL |
| 12 | alcohol-related disorders | 73.30% | DL |
| 13 | amelocerebrohypohidrotic syndrome | 73.06% | DL |
| 14 | Wernicke-Korsakoff syndrome | 72.65% | DL |
| 15 | autism, susceptibility to | 72.05% | DL |
| 16 | intellectual disability | 70.95% | DL |
| 17 | adenosarcoma | 70.71% | DL |
| 18 | uterine ligament adenosarcoma | 70.67% | DL |
| 19 | 16q24.3 microdeletion syndrome | 70.06% | DL |
| 20 | chromosome 15q11.2 deletion syndrome | 69.93% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.